07.01.2022 13:14:54

908 Devices: GSK Selects REBEL Desktop Device As Part Of Its Process Development Efforts

(RTTNews) - 908 Devices (MASS) announced that GlaxoSmithKline (GSK) has purchased an additional REBEL cell culture media analyzer. GSK will now have a total of five REBEL analyzers being used by its biologics and vaccine process development teams.

REBEL is the first miniature CE-MS-based analyzer that enables biopharma researchers to accelerate process development cycles and maximize bioreactor utilization by running media analysis at-line. 908 Devices noted that there are now 15 customers owning multiple REBEL devices, more than double from a year ago.

Analysen zu 908 Devices Inc Registered Shsmehr Analysen

Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

908 Devices Inc Registered Shs 2,78 -0,89% 908 Devices Inc Registered Shs